Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

PHASE3TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
AMI
Interventions
DRUG

Insulin Glargine (LANTUS)

Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL

DRUG

Insulin Glulisine (Apidra)

"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."

DRUG

Standard Therapy

Standard insulin therapy titrated to blood sugar control

Trial Locations (5)

Unknown

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Col. Coyoacan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY